<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TIGANÂ - trimethobenzamide hydrochlorideÂ capsuleÂ </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>TiganÂ®(trimethobenzamide hydrochloride)Capsules</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<a href="http://"></a><p class="First"></p>
<p>Chemically, trimethobenzamide HCl is N-[<span class="Italics">p</span>-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide monohydrochloride. It has a molecular weight of 424.93 and the following structural formula: </p>
<div class="Figure"><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=01a95f6d-f7d6-4ed1-a262-3c5848915252&amp;name=MM1.jpg"></div>
<p><span class="Bold">Capsules:</span> Each 300-mg TiganÂ  capsule for oral use contains trimethobenzamide hydrochloride equivalent to 300 mg. The capsule has an opaque purple cap marked â€œTiganâ€? and an opaque purple body marked â€œM079â€?. <span class="Bold">Inactive Ingredients:</span> D&amp;C Red No. 28, FD&amp;C Blue No. 1, lactose, magnesium stearate, starch and titanium dioxide.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="http://"></a><p class="First"></p>
<p><span class="Bold">Mechanism of Action</span></p>
<p>The mechanism of action ofÂ  TiganÂ  as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> center; direct impulses to the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> induced by intragastric copper sulfate.</p>
<p><span class="Bold">Pharmacokinetics</span></p>
<p>The pharmacokinetics of trimethobenzamide have been studied in healthy adult subjects. Following administration of 200 mg (100 mg/mL) Tigan I.M. injection, the time to reach maximum plasma concentration (T<span class="Sub">max</span>) was about half an hour, about 15 minutes longer for Tigan 300 mg oral capsule than an I.M. injection. A single dose of Tigan 300 mg oral capsule provided a plasma concentration profile of trimethobenzamide similar to Tigan 200 mg I.M. The relative bioavailability of the capsule formulation compared to the solution is 100%. The mean elimination half-life of trimethobenzamide is 7 to 9 hours. Between 30 â€“ 50% of a single dose in humans is excreted unchanged in the urine within 48-72 hours. The major pathway of trimethobenzamide metabolism is through oxidation resulting in the formation of trimethobenzamide N-oxide metabolite. The pharmacologic activity of this major metabolite has not been evaluated.</p>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Bold"><span class="Bold">Age</span></span></p>
<p>The clearance of trimethobenzamide is not known in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in elderly patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney and that elderly patients may have various degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (See <span class="Bold"><a href="#i4i_precautions_id_f3aeaa10-1b02-417c-a9a8-19e7cbe8382e">PRECAUTIONS</a>: <a href="#i4i_precautions_general_id_96f7393c-d4df-4b2b-88e3-c66911af935b">General</a></span> and <span class="Bold"><a href="#i4i_dosage_admin_id_80ea0cf0-7857-4d56-babd-6a1ef92f57eb">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p><span class="Bold">Gender</span></p>
<p>Systemic exposure to trimethobenzamide was similar between men (N=40) and women (N=28). </p>
<p><span class="Bold">Race</span></p>
<p>Pharmacokinetics appeared to be similar for Caucasians (N=53) and African Americans (N=12).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The clearance of trimethobenzamide is not known in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney. (See <span class="Bold"><a href="#i4i_precautions_id_f3aeaa10-1b02-417c-a9a8-19e7cbe8382e">PRECAUTIONS</a>: <a href="#i4i_precautions_general_id_96f7393c-d4df-4b2b-88e3-c66911af935b">General</a></span> and <span class="Bold"><a href="#i4i_dosage_admin_id_80ea0cf0-7857-4d56-babd-6a1ef92f57eb">DOSAGE AND ADMINISTRATION</a></span>). </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<a href="http://"></a><p class="First"></p>
<p>TiganÂ  is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> associated with <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>Use of any dosage form in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trimethobenzamide is contraindicated. </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a><p class="First"></p>
<p>Caution should be exercised when administering TiganÂ  to children for the treatment of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Antiemetics are not recommended for treatment of uncomplicated <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in children and their use should be limited to prolonged <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of known etiology. There are two principal reasons for caution:</p>
<p>1. The <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> which can occur secondary to TiganÂ  may be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with the central nervous system signs of an undiagnosed primary disease responsible for the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, e.g., Reyeâ€™s syndrome or other <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.</p>
<p>2. It has been suspected that drugs with hepatotoxic potential, such as TiganÂ , may unfavorably alter the course of Reyeâ€™s syndrome. Such drugs should therefore be avoided in children whose signs and symptoms (<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>) could represent Reyeâ€™s syndrome. </p>
<p>TiganÂ  may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined. </p>
<p><span class="Bold">Usage in Pregnancy:</span> Trimethobenzamide hydrochloride was studied in reproduction experiments in rats and rabbits and no <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was suggested. The only effects observed were an increased percentage of embryonic resorptions or stillborn pups in rats administered 20 mg and 100 mg/kg and increased resorptions in rabbits receiving 100 mg/kg. In each study these adverse effects were attributed to one or two dams. The relevance to humans is not known. Since there is no adequate experience in pregnant or lactating women who have received this drug, safety in pregnancy or in nursing mothers has not been established.</p>
<p><span class="Bold">Usage with Alcohol:</span> Concomitant use of alcohol with TiganÂ  may result in an adverse drug interaction.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>During the course of acute febrile illness, encephalitides, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, especially in children and the elderly or debilitated, CNS reactions such as <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> have been reported with and without use of TiganÂ  (trimethobenzamide hydrochloride) or other antiemetic agents. In such disorders caution should be exercised in administering TiganÂ , particularly to patients who have recently received other CNS-acting agents (phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed toward the restoration of body fluids and electrolyte balance, the relief of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and relief of the causative disease process. <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">Overhydration</span> should be avoided since it may result in <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>. The antiemetic effects of TiganÂ  may render diagnosis more difficult in such conditions as <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and obscure signs of toxicity due to overdosage of other drugs.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Adjustment of Dose in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></p>
<p>A substantial route of elimination of unchanged trimethobenzamide is via the kidney. Dosage adjustment should be considered in patients with reduced renal function including some elderly patients. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_ac0fc80d-6116-4a6e-b131-64279b2fa8bf">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#i4i_dosage_admin_id_80ea0cf0-7857-4d56-babd-6a1ef92f57eb">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p><span class="Bold">Geriatric Use</span></p>
<p>Clinical studies of trimethobenzamide hydrochloride did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Although there are studies reported in the literature that included elderly patients &gt; 65 years old with younger patients, it is not known if there are differences in efficacy or safety parameters for elderly and non-elderly patients treated with trimethobenzamide. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_ac0fc80d-6116-4a6e-b131-64279b2fa8bf">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#i4i_dosage_admin_id_80ea0cf0-7857-4d56-babd-6a1ef92f57eb">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> and Parkinson-like symptoms. There have been instances of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> reported following parenteral administration to surgical patients. There have been reports of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of mood, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> and <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>. If these occur, the administration of the drug should be discontinued. Allergic-type <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been observed; therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<a href="http://"></a><p class="First"></p>
<p>(See<span class="Bold"><a href="#i4i_warnings_id_0f62906c-5b24-444f-b16a-3e7da1a4309f"> WARNINGS</a></span> and <span class="Bold"><a href="#i4i_precautions_id_f3aeaa10-1b02-417c-a9a8-19e7cbe8382e">PRECAUTIONS</a></span>.)</p>
<p>Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.</p>
<p><span class="Bold">Geriatric Patients</span></p>
<p>Dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered in elderly patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance â‰¤ 70 mL/min/1.73m<span class="Sup">2</span>). Final dose adjustment should be based upon integration of clinical efficacy and safety considerations. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_ac0fc80d-6116-4a6e-b131-64279b2fa8bf">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#i4i_precautions_id_f3aeaa10-1b02-417c-a9a8-19e7cbe8382e">PRECAUTIONS</a></span>).</p>
<p><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>In subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance â‰¤ 70 mL/min/1.73m<span class="Sup">2</span>), dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_ac0fc80d-6116-4a6e-b131-64279b2fa8bf">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#i4i_precautions_id_f3aeaa10-1b02-417c-a9a8-19e7cbe8382e">PRECAUTIONS</a></span>). </p>
<p>CAPSULES, 300 mg</p>
<p><span class="Italics">Usual Adult Dosage</span></p>
<p>One 300 mg capsule t.i.d. or q.i.d.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<a href="http://"></a><p class="First"></p>
<p>Store at 25Â°C (77Â°F).</p>
<p>Excursions permitted to 15â€“30Â°C (59â€“86Â°F).</p>
<p>[See USP Controlled Room Temperature]</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<a href="http://"></a><p class="First"></p>
<p>Capsules, 300 mg trimethobenzamide hydrochloride each, bottles of 100 </p>
<p><span class="Bold">NDC</span> 61570-079-01 300 mg 100â€™s</p>
<p><span class="Bold">RX ONLY</span></p>
<p>Prescribing Information as of April 2008.</p>
<p>Distributed By: Monarch Pharmaceuticals, Inc., Bristol, TN 37620</p>
<p>(A wholly owned subsidiary of King Pharmaceuticals, Inc.)</p>
<p>Manufactured By: King Pharmaceuticals, Inc., Bristol, TN 37620</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
    DRUG: TIGAN <br>GENERIC: trimethobenzamide hydrochloride<br>DOSAGE: CAPSULE<br>ADMINSTRATION: ORAL<br>NDC: 52125-143-08<br>STRENGTH:300 mg<br>COLOR: purple<br>SHAPE: CAPSULE<br>SCORE: No score<br>SIZE: 20 mm<br>IMPRINT: 30<br>QTY: 30<br><br><div class="Figure"><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=01a95f6d-f7d6-4ed1-a262-3c5848915252&amp;name=MM2.jpg"></div>
<div class="Figure"><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=01a95f6d-f7d6-4ed1-a262-3c5848915252&amp;name=MM3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIGANÂ 		
					</strong><br><span class="contentTableReg">trimethobenzamide hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-143(NDC:61570-079)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIMETHOBENZAMIDE HYDROCHLORIDE</strong> (TRIMETHOBENZAMIDE) </td>
<td class="formItem">TRIMETHOBENZAMIDE HYDROCHLORIDE</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">purple</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Tigan;M079</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-143-08</td>
<td class="formItem">30  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017531</td>
<td class="formItem">03/11/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4f0b1d89-9951-44d7-b4e9-4810e88f5112</div>
<div>Set id: 01a95f6d-f7d6-4ed1-a262-3c5848915252</div>
<div>Version: 1</div>
<div>Effective Time: 20130311</div>
</div>
</div>Â <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
